Trial · NCT01261767
First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
NCT01261767, Phase 1, Terminated, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects. Trials, record NCT01261767. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01261767
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
- NCT number
- NCT01261767
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 55 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Inflammation, Psoriasis
- Interventions
- anti-IL-20, placebo
- First posted
- 2010-12-16
- Last updated
- 2017-02-09
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Observed toxicity using the US National Cancer Institute's common terminology criteria for adverse events (CTCAE) - SD phase | from week 0 until end of trial observation period at week 16 | |
| Primary | Observed toxicity using the US National Cancer Institute's common terminology criteria for adverse events (CTCAE) - MD and MD expansion phases | from week 0 until end of trial observation period at week 22 | |
| Primary | Improvement psoriasis area and severity index score by 75% (PASI75) - MD expansion phase | at weeks 1-7, 9-15, 22 | |
| Secondary | Observed toxicity using the US National Cancer Institute's common terminology criteria for adverse events (CTCAE) - MD expansion phase | from week 0 until end of trial observation period at week 22 | |
| Secondary | Improvement psoriasis area and severity index score by 75% (PASI75) - SD and MD phases | SD: at weeks 1, 3, 9, 13 and 16. MD: at weeks 1, 3, 5, 7, 9, 15, 22 | |
| Secondary | Pharmacokinetics (the rate at which the body eliminates the trial drug) - SD and MD phases | SD: Prior to dosing (week 1) and through 24 hours and at each visit (week 1-3, 5, 9, 13 and 16). MD: Prior to dosing and at each dosing visit (week 1, 3, 5, 7) | |
| Secondary | Pharmacokinetics (the rate at which the body eliminates the trial drug) - MD expansion phase | prior to dosing (week 1) and at each dosing visit (week 2-7) | |
| Secondary | Pharmacodynamics (the effect of the investigated drug on the body) - SD and MD phases | SD: Prior to dosing (week 1) and through 24 hours and at each visit (week 1-3, 5, 9, 13 and 16). MD: Prior to dosing and at each dosing visit (week 1, 3, 5, 7) | |
| Secondary | Pharmacodynamics (the effect of the investigated drug on the body) - MD expansion phase | prior to dosing (week 1) and at each dosing visit (week 2-7) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01261767
GET https://conductscience.org/api/trials/v1/NCT01261767/registered